Literature DB >> 19133927

Cardiac allograft hypertrophy: a new target for therapy, a surrogate marker for survival?

G Torre-Amione.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19133927     DOI： 10.1111/j.1600-6143.2008.02503.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN： 1600-6135            Impact factor:   8.086


× No keyword cloud information.
  6 in total

1.  Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis.

Authors:  Adam J Booth; Sherri C Wood; Ashley M Cornett; Alyssa A Dreffs; Guanyi Lu; Andrés F Muro; Eric S White; D Keith Bishop
Journal:  J Pathol       Date:  2012-01-04       Impact factor: 7.996

2.  Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation.

Authors:  Eugenia Raichlin; Malik A Al-Omari; Courtney L Hayes; Brooks S Edwards; Robert P Frantz; Barry A Boilson; Alfredo L Clavell; Richard J Rodeheffer; John A Schirger; Sudhir S Kushwaha; Thomas G Allison; Naveen L Pereira
Journal:  J Heart Lung Transplant       Date:  2011-05-31       Impact factor: 10.247

Review 3.  TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection.

Authors:  Adam J Booth; D Keith Bishop
Journal:  Immunotherapy       Date:  2010-07       Impact factor: 4.196

4.  Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection.

Authors:  A J Booth; K Csencsits-Smith; S C Wood; G Lu; K E Lipson; D K Bishop
Journal:  Am J Transplant       Date:  2009-09-25       Impact factor: 8.086

5.  Critical role for IL-6 in hypertrophy and fibrosis in chronic cardiac allograft rejection.

Authors:  J A Diaz; A J Booth; G Lu; S C Wood; D J Pinsky; D K Bishop
Journal:  Am J Transplant       Date:  2009-06-16       Impact factor: 8.086

6.  TGFbeta neutralization within cardiac allografts by decorin gene transfer attenuates chronic rejection.

Authors:  Susan M Faust; Guanyi Lu; Sherri C Wood; D Keith Bishop
Journal:  J Immunol       Date:  2009-11-16       Impact factor: 5.422
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.